Table 1.
Baseline characteristic of patients
| n = 60 (%) | ||
|---|---|---|
| Age | < 60 | 28 (46.7%) |
| ≥ 60 | 32 (53.3%) | |
| Sex | Female | 12 (20.0%) |
| Male | 48 (80.0%) | |
| ECOG performance status | 0 | 9 (15.0%) |
| 1 | 51 (85.0%) | |
| Pathologic confirmation | No | 0 (0.0%) |
| Yes | 60 (100%) | |
| Child-Pugh classification | A5 | 41 (68.3%) |
| A6 | 19 (31.7%) | |
| Etiology | Hepatitis B | 46 (76.7%) |
| Hepatitis C | 6 (10.0%) | |
| Alcohol | 1 (1.7%) | |
| Primary biliary cirrhosis | 1 (1.7%) | |
| Others | 6 (10.0%) | |
| Alpha-fetoprotein | ≥ 400 | 30 (50.0%) |
| < 400 | 30 (50.0%) | |
| Extrahepatic disease | No | 8 (13.3%) |
| Yes | 52 (86.7%) | |
| Prior treatment | Transplantation | 0 (0.0%) |
| Surgery | 17 (28.3%) | |
| Locoregional therapy (RFA, TACE) | 41 (68.3%) | |
| Radiotherapy | 31 (51.7%) | |
| Prior chemotherapy | 1 | 48 (80.0%) |
| ≥ 2 | 12 (20.0%) | |
| Prior sorafenib | No | 0 (0.0%) |
| Yes | 60 (100%) | |
ECOG, Eastern Cooperative Oncology Group; RFA, radiofrequency ablation; TACE, transarterial chemoembolization